U.S. markets closed
  • S&P 500

    3,719.04
    +71.75 (+1.97%)
     
  • Dow 30

    29,683.74
    +548.75 (+1.88%)
     
  • Nasdaq

    11,051.64
    +222.13 (+2.05%)
     
  • Russell 2000

    1,715.24
    +52.73 (+3.17%)
     
  • Crude Oil

    81.79
    -0.36 (-0.44%)
     
  • Gold

    1,666.10
    -3.90 (-0.23%)
     
  • Silver

    18.86
    -0.01 (-0.08%)
     
  • EUR/USD

    0.9718
    -0.0021 (-0.21%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • GBP/USD

    1.0846
    -0.0039 (-0.36%)
     
  • USD/JPY

    144.3890
    +0.2670 (+0.19%)
     
  • BTC-USD

    19,530.82
    +433.90 (+2.27%)
     
  • CMC Crypto 200

    447.10
    +18.32 (+4.27%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

Reata Pharmaceuticals: Q2 Earnings Insights

·1 min read

Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 7.89% year over year to ($1.23), which beat the estimate of ($2.84).

Revenue of $3,073,000 decreased by 60.77% from the same period last year, which beat the estimate of $1,040,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Aug 10, 2020

View more earnings on RETA

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/hr8ew88f.

Recent Stock Performance

Company's 52-week high was at $257.96

52-week low: $70.00

Price action over last quarter: down 5.64%

Company Overview

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.